Your Javascript appears to be disabled. In order to experience Universe, you need to turn your Javascript on.

The European Medical Cannabis Conference 2019

Dentons, Markgrafenstraße 33, 10117 Berlin, Germany

Berlin, Germany Berlin

52.52000659999999 13.404953999999975

Description

The Cannabis Society, with support from Dentons and FTI Consulting, has put together a distinguished two day medical cannabis conference. Come join us and hear presentations and panels from researchers, lawmakers, regulatory experts, economists and industry experts discuss the current state of medical cannabis science, cannabis application, laws and market trends within the European Union and abroad. The Cannabis Society (TCS) is an organization focused on progressing the medical cannabis industry in Europe. TCS runs highly-curated, invite-only, professional-only conferences that brings together top cannabis researchers, medical professionals, industry executives, investors and service providers. TCS is a global organization hosting conferences and events in markets including Europe, North America, South America, Israel and Australia. EVOLVING SCHEDULE: DAY ONE: MEDICAL Time TUESDAY 9:00 AM Registration (Light Breakfast Served) 10:00 AM Opening Remarks by The Cannabis Society 10:15 AM Keynote: What is Cannabis / What are Canabanoids Speaker: Dr. Adam Norris, MD, DABFM, CCFP 11:00 AM Panel Discussion: Dosage & Usage of Cannabis Moderator: Dr. Jonas Vanderzwan, MD, CCFP Panelists: Aras Azadian (CEO, Chairman and Co-Founder, Avicanna), Dr. Robert Pawinski (Chief Medical Officer, Althea), Patricia Frye, MD (Chief Medical Officer, Hello MD), Tim Dresseman (Research Analyst, Deutsches Institut für Medizinalcannabis) 11:45 AM Keynote: TBC Speaker: Peter Homberg (Partner, Dentons) 12:15 PM Keynote: TBC Speaker: Patricia Frye M.D (Chief Medical Officer, Hello MD) 1:00 PM Break (Light Lunch Served) 2:00 PM Panel Discussion: The Cannabis Supply Chain Moderator: Boris Moshkovits (Co-founder & Managing Director, alephSana) Panelists: Linus Weber (Founder & CEO at Nimbus Health GmbH), Rick Brar (CEO & Chairman at Brains Bioceutical Corp.), Juriën Koster (Vice-President International Relations, Ofinext and Director at C.I.E.), Benjamin Patock (Head of International Relations, Boveda) 2:45 PM Keynote: Use of Medical Cannabis and the Elderly Speaker: Dr. Jonas Vanderzwan, MD, CCFP 3:15 PM Keynote: TBC Speaker: Dr. Hartmut Vennen (Senior Managing Director, FTI Consulting) 3:45 PM Keynote: TBC Speaker: Tjalling Erkelens 9Founder & CEO, Bedrocan) 4:15 PM Closing Remarks by The Cannabis Society 4:30 PM Networking 6:00 PM Conference Ends DAY TWO: INVESTOR Time WEDNESDAY 9:00 AM Registration (Light Breakfast Served) 10:00 AM Opening Remarks by The Cannabis Society 10:15 AM Keynote: TBC Speaker: Peter Homberg (Partner, Dentons) 10:45 AM Keynote: TBC Speaker: Dr. Marc Christian Theurer (Senior Director, FTI Consulting) 11:15 AM Panel Discussion: Licensed Producers Moderator: Ole Heil, (Director PR & Communications, Bedrocan) Panelists: Boris, Blatnik (CEO, KannaSwiss AG), Gregg Battersby (Managing Director, Europe, Athlea), Jens Kramer (Vice President, Europe Operations, Avicanna) 12:00 PM Keynote: TBC Speaker: Larry Lisser (SVP, Business Development, Hello MD) 12:30 PM Break (Light Lunch Served) 1:30 PM Panel Discussion: How Software Technology Intersects with the Industry Moderator: TBC Panelists: Marguerite Arnold (CEO, MedPayRx UG), Larry Lisser (SVP, Business Development, Hello MD), Prad Sekar (CEO, CB2 Insights) 2:15 PM Panel Discussion: Investing in Cannabis Moderator: Moritz Förster, Founder, krautinvest.de Panelists: Simon Tankel (President, Wundr Co.), Melissa Sturgess (Chief Executive Officer, Ananda Developments Plc) 3:00 PM Keynote: TBC Speaker: Shea Coulson (Partner, Dentons) 3:30 PM Closing Remarks by The Cannabis Society 3:45 PM Networking 5:00 PM Conference Ends CONFIRMED PARTICIPANTS: Boris, Blatnik, CEO, KannaSwiss AG Boris serves as CEO of KannaSwiss. He joined the team January of 2017 and has been instrumental in the rebranding and business development of the company. Prior to KannaSwiss Boris served as CSO and Co-founder of Numbridge Inc. from 2009 until 2016. Numbridge was a telecommunication app that helped people communicate over the GSM network. Boris served as CEO & Co-founder of Atlas Commercial Holdings from 2004 until 2009. Atlas established an interlocking network of global business alliances and partnerships to provide customized solutions that enable governments and local businesses in emerging markets to stabilize and upgrade their basic infrastructures. Formerly he was Founder & President of V Karting, an integrated go-kart facility with conference rooms, restaurant and entertainment/game space. His experiences range from construction to telecommunications to natural resource consulting working with such companies as MAN Ferrostaal and Petrobras. Boris earned his A-levels from Aiglon College in Villars, Switzerland and then attended American University in Washington, DC. Born in Caracas, Venezuela, Boris was raised in Switzerland and moved to the U.S. to attend university. He is fluent in English, Spanish, French, German, Italian, and Portuguese. Patricia Frye M.D, Chief Medical Officer, Hello MD Patricia Frye M.D.is Chief Medical Officer of HelloMD and began her journey with medicinal cannabis as the first evaluating physician on the company’s digital healthcare platform. She is professionally certified by the University of Vermont School of Medicine in Cannabis Science and Medicine and serves on the board of the Cannabis Trade Federation and the Society of Cannabis Clinicians. As an adjunct faculty member in Cannabis Medicine at the University of Maryland School of Pharmacy, she lectures nationally, educating medical providers, patient groups, policy makers, and government agencies on the medical benefits of cannabis. In 2018 she authored and published the book “The Medical Marijuana Guide: Cannabis and Your Health”. She is also the founder and medical director of Takoma Park Integrative Care. Her practice focuses on the role of cannabis in the management of chronic pain, inflammation, autoimmunity, neurodegenerative disorders, autism, insomnia, and psychiatric conditions and over the years has evaluated and advised thousands of patients on the use of medical cannabis. Dr. Frye works closely with patients residing in Maryland, Virginia, and Washington, DC and with referring clinicians, including those at the University of Maryland, Johns Hopkins University, and the Children’s National Medical Center, to develop sound treatment plans that are based on both observational and scientific evidence. Tjalling Erkelens, Founder & CEO, Bedrocan Tjalling Erkelens (1956) is the founder of Bedrocan and currently holds the position of CEO / chairman of the board. Back in 1984 he started Bedrocan in the Netherlands together with his brother in law Freerk Bruining, focussing on indoor production of vegetables and herbs. Tjalling is strongly committed to maintain these family business roots especially now Bedrocan continues to grow. The cannabis plant came into the company back in 1992 for the first time. Since 2003 Bedrocan provides standardised cannabis of pharmaceutical quality to the Dutch government. It’s the oldest legal company in the world providing several, chemically different cannabis varieties to be used by patients on doctor’s prescription and as a raw material for the pharmaceutical industry (API). During these past 26 years, Tjalling has developed and standardised unique methods of producing cannabis to pharmaceutical standards to a level achieved by no other company until today. His strong commitment to product quality resulted in the Dutch Bedrocan production facilities being approved for GMP/API (Good Manufacturing Practice/Active Pharmaceutical Ingredients) by the Dutch Health Authorities in 2017. Dr. Robert Pawinski, Chief Medical Officer, Althea Dr Robert Pawinski is an experienced Pharmaceutical Physician in both academia and industry. Robert has led a clinical, epidemiology and Health economics research team where he was principal investigator in multiple trials, as well as working as a clinician in the private and public sector in the UK and abroad. Robert has extensive senior experience in two of the Big-Five Global Pharma, and small and mid-sized pharmaceutical companies in a leadership role as QPPV, EU Medical Director. Robert also has experience working at a senior government level with bodies like the WHO, NICE, the MHRA and EMA. Dr Pawinski also has deep knowledge of the EU and Emerging markets from an access and clinical trial perspective, with over 27 peer review publications on pain and infectious diseases which include the Lancet and JAIDS. Gregg Battersby Managing Director, Europe, Athlea Providing commercial leadership in the EU, with extensive experience in the global medical cannabis industry. Formally VP of Commercial Strategy for Canadian licenced cannabis producer, Aphria Inc. Overseeing commercial aspects of Althea’s European strategy, including business development, supply chain management and operational execution Dean Billington is COO of Brains Bioceutical, a leading GMP-certified producer and distributor of naturally sourced Active Pharmaceutical Ingredients (API). Mr. Billington began his career working with pharmaceutical CBD as an executive at GW Pharma. Dean brings a wealth of experience in the global pharmaceutical industry having held previous senior leadership positions, including Global QA at Caligor Rx and Director at Fisher Clinical Services for over six years. Mr. Billington holds a BSc in Chemical Engineering and Applied Chemistry from Huddersfield University. Dr. Jonas Vanderzwan, MD, CCFP Canadian physician with 15 years of primary care experience, and extensive experience in the use medical cannabis. As lead physician of a local cannabis clinic, he has been involved in the assessment and care of approximately 1500 patients, using cannabis as a treatment in a wide range of clinical conditions. As an early adopter of cannabis as a therapeutic agent, he has had the opportunity to travel the World, educating other medical professionals and patient groups on both the use and potential benefits of cannabis. Dr. Vanderzwan is an active consultant in the medical cannabis environment, having worked with both private and public players in the space, and since 2018 has been serving as Medical Director, and Chair of the Medical Advisory Board, for a Health Canada approved Licensed Producer of medical cannabis. In addition to ongoing membership in several international cannabinoid medicine organizations, Dr. Vanderzwan has most recently been appointed Vice-Chair of the Ontario Medical Association’s medical cannabis interest group. Dr. Adam Norris, MD, DABFM, CCFP Adam Norris has been working as a physician in Brantford, Ontario for the past 5 years.He completed his undergraduate studies at Dalhousie University in Neuroscience.Adam received his medical degree from Ross University and did a Family medicine residency at Northeastern University School of Medicine in Ohio. He is board certified in both Canada and the USA.Dr. Norris is a Family Physician and Medical Director of GreenDot Medical Center, Cannabinoid Clinic.He is currently Assistant Clinical Professor for Faculty of Family Medicine and Associate Professor at the MGD Centre for Medicinal Cannabis Research.This past year, he has taken a role as a consultant for Addiction Medicine at Brantford General Hospital. Peter Homberg, Partner, Dentons Peter Homberg is a partner in the Dentons Berlin office. He focuses on life sciences, IP, corporate law and M&A transactions in the life sciences and high-tech sector as well as in R&D and cooperation agreements, cross-border IP licensing and IP strategies. Furthermore, he has extensive experience providing legal advice on compliance issues. Additionally, he is the head of the European Cannabis sector group. Peter advises inter alia companies in the pharmaceutical, diagnostics, biotechnology, medical device and medical cannabis industries—from startups to large publicly listed companies. Furthermore, he has broad transactional experience in Southeast Asia. Peter is member of the Licensing Executive Society (LES), the German Association for Intellectual Property and Copyright (GRUR), the German Institution for Arbitration (DIS) as well as the Pharma-Lizenz-Club Deutschland e.V. He regularly holds lectures at seminars and conferences. He is the author of numerous professional articles and other publications regarding corporate or IP law in the field of life sciences. Melissa Sturgess, Chief Executive Officer of Ananda Developments Plc Melissa Sturgess holds a BSc and an MBA and has more than 20 years of experience as a director of UK and Australian Stock Exchange quoted companies, mainly involved in the acquisition, structuring and financing of natural resources deals across Africa. Miss Sturgess commenced her career in Australia as a member of the Executive Committee of Aquarius Platinum Limited, one of the first Australia/UK dual listed companies and a miner of platinum in South Africa and Zimbabwe. She was also founding director of Sylvania Resources Limited and a number of other companies operating in the metals and mining sector throughout Africa and listed on the AIM Market in London. Miss Sturgess relocated to London in 2006 and during her career has raised significant amounts of capital. She was a key driver in the successful recapitalisation of Messaging International plc during 2016 which subsequently changed its name to SigmaRoc Plc, acquired a building materials business via a reverse takeover and raised £50 million from a range of investors in the Channel Islands and the UK. Miss Sturgess’ interest in the cannabis sector started in 2017 with a trip to Israel to review the Medicinal Cannabis research that is happening in that country. She subsequently founded Ananda Developments to invest in the space and is its largest shareholder. Moritz Förster, Founder, krautinvest.de Moritz Förster is running specific cannabis communication services together with Openers, Berlin's facilitator for innovation and entrepreneurship. He has been Farmako's Head of PR, one of the leading German distributors. Moritz is also the founder of Germany's online B2B magazine for the legal cannabis industry krautinvest.de. Juriën Koster,Vice-President International Relations at Ofinext and Director at C.I.E. Active in the cannabis industry since 2017. Help to build four different companies from the ground up. Actively developing a professional cannabis industry in The Netherlands and Europe. Occasional speaker at cannabis conventions and advisor to trade shows and events. Expertise in the technical and pharmaceutical aspects of the market. International spokesperson for Ofinext. Building and maintaining a broad network of different stakeholders with a focus on the pharmaceutical aspect of the market. Developing our own Ofinext pharmaceutical products (EU-GMP certified full spectrum API's) and looking for new possibilities. Lead role in the Ofinext clinical trials. In charge of project management and making strategic decisions regarding the trials. Actively lobbying for the cannabis industry in Europe and most notably The Netherlands, by organizing cannabis events and the development of a scientific cannabis center in Wageningen. Marguerite Arnold, CEO, MedPayRx UG Marguerite Arnold is a cannabis industry journalist and high tech entrepreneur. She is also the founder of MedPayRx, a unique, compliant seed to sale and digital prescriptions, authorization and payment platform. Dr. Marc Christian Theurer, Senior Director, FTI Consulting He advises companies on their corporate positioning and in special situations. Marc supports his clients in protecting their freedom to operate, meeting their business objectives and in building their reputation among their stakeholders. Over the last twelve years, he has supported a variety of companies from different industries in mission-critical situations requiring an integrated approach targeted at politics and the media. Marc has a particular expertise in the chemicals and pharmaceuticals industry. Before joining FTI Consulting, Marc worked as Director in the corporate affairs team of the managing consulting firm Hering Schuppener. Prior to that, he worked for six years for the consultancy CNC where he set up CNC’s Brussels office. Marc holds a PhD in Modern History. Dr. Hartmut Vennen, Senior Managing Director, FTI Consulting Hartmut Vennen is a Senior Managing Director in the Strategic Communications segment at FTI Consulting and is based in Frankfurt. For over 25 years, he advises clients on all aspects of communications in success critical crisis and transformation situations in order to help them protect and enhance their reputation and achieve their business ambitions. Hartmut is a recognized sector specialist in Healthcare, Life Sciences and Chemicals and leads FTI Consulting's Corporate Reputation practice in Germany. One particular focus of his work is on the management of reputational risks. Typical assignments include all aspects of communications in high level crisis situations, legal disputes (litigation, prosecution, international arbitration, product liability and product recalls) and compliance related issues (competition, anti trust, data and cyber security, money laundering or corruption/FCPA related issues). Hartmut also helps clients to systematically build and enhance their reputation, following an in-depth stakeholder communications and engagement approach at the intersection of communications and leadership. He also supports companies and organizations in large scale transformation and change programs. Typical situations include Performance and Efficiency Improvements (Supply Chain Restructurings, Business Process Outsourcing, Manufacturing Footprint Optimizations), Restructurings (Site Closures, Lay-Offs), Cultural Change (Compliance and Integrity Improvements) or Post Merger Integration projects. He also advises international organizations on communications governance issues. Before joining FTI Consulting, Hartmut was a partner at an international communications advisory firm and had senior international communication functions at Merck KGaA, Clariant and Hoechst. Hartmut holds a Ph.D. (Chemistry) from RWTH Aachen University of Technology and is a certified Prosci® Change Management Practitioner. Benjamin Patock, Head of International Relations, Boveda Benjamin cares for one thing: To secure high quality standards for cannabis products around the globe. As Head of International Relations for Boveda (http://www.bovedainc.com), the global leader in 2-way humidity control, he is at the center of this movement, as water activity is one of the most dominant factors for product quality and safety. Boveda, celebrating over 20 years in business, produces a very natural, reliable, stable, safe and at the same time inexpensive and disposable device that controls humidity levels by adding and removing water content within any type of closed container. Prior to his engagement at Boveda, Benjamin’s career included a turn as a product and marketing specialist. Prior to his studies, he designed his first online projects in 1999 which lead him to different roles for big agencies and corporations alike. In 2006 he took a leap of faith and joined a friend in his freshly founded start-up and stayed in this ecosystem founding two companies of his own. The most recent one, Noblego (http://www.noblego.de), is today one of the leading European retailers of cigars and premium tobacco products. Benjamin lectured at University level, wrote one of the best-selling cigar books in German language (http://amzn.to/2BP70H2) and acts as speaker and activist for consumer rights groups. He now takes his experiences from a highly regulated tobacco market to bring high-quality cannabis medicine to anyone who needs it, no matter location. Boris Moshkovits, Co-founder and Managing Director, alephSana Boris Moshkovits is a Cannapreneur and experienced founder with a demonstrated history of working in the media, pharma and internet industry. He is the co-founder and managing director of alephSana, a company focused on scouting for qualified medical cannabis products globally and on bringing the best cannabis therapeutics to Germany and Europe. Moshkovits has served as International digital marketing manager in the pharma industry walking the fine line of marketing and digital storytelling in highly regulated markets. As a speaker Moshkovits has been talking about the mainstreaming of medical cannabis and the future of cannabis as a lifestyle product. He is also the co-founder of the CannaBusinessClub.Berlin, an initiative to empower the local cannabis scene. In his publishing career, he was the head of digital media for Ringier Publishing Germany and publisher of Amuse for Vice Media Germany. Prior to this, he has worked as an editor and publisher in Milan, Moscow and New York. Simon Tankel, President, Wundr Co. Simon is the President of Wundr. His previous cannabis experience includes founding Golders Hill (merged into Wundr), Ark Wellness and an investment practice for a family office. Previously, he was Head of Business Development at Sum International, focusing on power plant development and latterly cannabis investing. Linus Maximilian Weber is an experienced Business Consultant, Founder and Chief Executive in the health care industry. Linus has been working at Ernst & Young in the Compliance and Quality Management Consulting unit prior joining Fresenius Medical Care the worlds leading company in renal care. He is a certified Project Management Consultant and GDP Responsible for the pharmaceutical distribution business. In 2018 after building the Compliance Management System at Fresenius he founded Nimbus Health a fully licensed pharmaceutical wholesaler in Germany, where he serves as Chief Executive Officer. The focus of Nimbus Health is to improve the wellbeing of patients by giving consistent and standardized access to alternative therapies based on Medicinal Cannabis and to reshape the health care system by developing additional Cannabis products. Aras Azadian, CEO, Chairman and Co-Founder, Avicanna Utilizing his extensive senior management experience in both financial and bio-technology sectors, Aras co-founded Avicanna with the vision of establishing a bio-pharmaceutical company with a strict focus on medical and pharmaceutical applications of cannabinoids. His expertise in corporate development coupled with his executive experience in the oncology industry have been integral to Avicanna’s thought leadership pertaining to R&D and clinical development. Since 2016 Aras has successfully led a team of executives, scientists and medical professionals across several countries with the vision of vertical integration and a strong company focus on quality controls, scientific vigour and competitive advantages. Aras holds a Bachelor of Economics degree from York University and an International Masters in Management degree from EADA Business School in Barcelona, Spain. Ole Heil, Director PR & Communications, Bedrocan Ole Heil has a Master’s degree in Public and Constitutional Law and a Master’s Degree in History. He worked as the international officer for the Dutch People’s Party for Freedom and Democracy (VVD) from 2009-2012. After that he has been the spokesperson to the minister of Health, Welfare and Sports in The Netherlands from 2012 – 2019. First 5.5 years for Ms. Edith Schippers, then 1.5 years for mr. Bruno Bruins. In this role he became closely acquainted with the development of Dutch medicinal cannabis regulations. Since March 2019 he is the director of Public Relations and Communications for Bedrocan, also responsible for Government and Public Affairs. Besides his professional job, he is a city council member in the municipality of Leidschendam-Voorburg (75.000 inh.) and vice-chairs a fraction of 9. Tim Dresemann, Deutsches Institut für Medizinalcannabis "I was always interested in medicinal plants and especially Cannabis. After studying agricultural sciences and my first job as an agricultural consultant for the cultivation of medicinal plants, I went back to university to work as a research associate. All the while, I was waiting for legal opportunities to work in the field of Cannabis. In November 2018 I found such an opportunity and started working as a Research Analyst for the German Institute for Medicinal Cannabis (DIFMC). Here, I could finally take a deep dive into large parts of the cannabis-related scientific literature. Since cultivation is just starting here in Germany, my focus has been almost exclusively on medicinal aspects of Cannabis." Shea Coulson, Partner, Dentons Canada LLP Shea Coulson is a partner with Dentons Canada LLP and is the national lead of regulatory of the firm’s Canadian cannabis practice. Shea has extensive experience providing regulatory advice to licensed producers, licensed retailers, warehousing and distribution companies, logistics firms, and investors in relation to corporate transactions, financing, commercial agreements, and compliance and enforcement. Shea regularly deal with Health Canada and the provincial regulators in relation to cannabis regulation. Shea also has 10 years of experience advising companies in liquor law and regulation. The regulators of these industries overlap with cannabis regulation at the provincial level. Shea also has a practice in commercial and regulatory litigation. Shea is located in Dentons’ Vancouver, British Columbia office. SPONSORS MEDIA SPONSOR If you are an established national or international company, and are looking to learn more about the cannabis space, please reach out to manager@thecannabissociety.org for more information. ***More information about the Cannabis Society here.

This listing has no upcoming events

Start: 2019-09-24T09:00:00+02:00

End: 2019-09-25T16:00:00+02:00